Artículos de revistas
Consensus Of Systemic Lupus Erythematosus [consenso De Lúpus Eritematoso Sistêmico]
Registration in:
Revista Brasileira De Reumatologia. , v. 48, n. 4, p. 196 - 207, 2008.
4825004
2-s2.0-58149131237
Author
Borba E.F.
Latorre L.C.
Brenol J.C.T.
Kayser C.
da Silva N.A.
Zimmermann A.F.
de Padua P.M.
Costallat L.T.L.
Bonfa E.
Sato E.I.
Institutions
Abstract
[No abstract available] 48 4 196 207 Bus, V., Maury, E.E., Hochberg, M.C., The epidemiology of systemic lupus crythematosus (2007) Dubois lupus crythematosus, pp. 34-44. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins; Tan, E.M., Cohen, A.S., Fries, J.F., The 1982 revised criteria for the classification of systemic lupus erythematosus (1982) Arthritis Rheum, 25, pp. 1271-1277 Hochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (1997) Arthritis Rheum, 40, p. 1725 Dellavance, A., Gabriel, A., Cintra, A.F.U., II Consenso Brasileiro de Fator Antinuclear em Células HEP-2. Dcfinições para padronização da pesquisa contra constituintes do núcleo, nucléolo, citoplasma e aparelho mitótico e suas associações clínicas. (2003) Rev Bras Reumatol, 43, pp. 129-140 Wallace, D.J., Principles of therapy and local measures (2007) Dubois lupus erythematosus, pp. 1132-1144. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins; Tench, C.M., McCarthy, J., McCurdie, I., Fatigue in systemic lupus erythematosus: A randomized controlled trial of exercise (2003) Rheumatology (Oxford), 42 (9), pp. 1050-1054 Keyser, R.E., Rus, V., Cade, W.T., Kalappa, N., Flores, R.H., Handwerger, B.S., Evidence for aerobic insufficiency in women with systemic Lupus erythematosus (2003) Arthritis Rheum, 49 (1), pp. 16-22 Carvalho, M.R., Sato, E.I., Tebexreni, A.S., Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus (2005) Arthritis Rheum, 53 (6), pp. 838-844 Ayán, C., Martín, V., Systemic Jupus erythematosus and exercise (2007) Lupus, 16 (1), pp. 5-9 Measurement of fatigue in systemic lupus erythematosus: A systematic review (2007) Arthritis Rheum, 57 (8), pp. 1348-1357. , Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue Carvalho, J.F., Blank, M., Kiss, E., Anti-vitamin D, vitamin D in SLE: Preliminary results (2007) Ann N Y Acad Sci, 1109, pp. 550-557 Kamen, D.L., Cooper, G.S., Bouali, H., Vitamin D deficiency in systemic lupus erythematosus (2006) Autoimmun Rev, 5 (2), pp. 114-117 Rahman, P., Gladman, D.D., Urowitz, M.B., Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus (1998) J Rheumatol, 25 (9), pp. 1716-1719 Jewell, M.L., McCauliffe, D.P., Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment (2000) J Am Acad Dermatol, 42 (6), pp. 983-987 Ghaussy, N.O., Sibbitt Jr, W., Bankhurst, A.D., Qualls, C.R., Cigarette smoking and disease activity in systemic lupus erythematosus (2003) J Rheumatol, 30 (6), pp. 1215-1221 Westerweel, P.E., Luyten, R.K., Koomans, H.A., Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus Arthritis Rheum 20071, 56 (5), pp. 1384-1396 Meinao, I.M., Sato, E.I., Andrade, L.E., Controlled trial with chloroquine diphosphate in systemic lupus erythematosus (1996) Lupus, 5, pp. 237-241 A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus (1991) N Engl J Med, 324, pp. 150-154. , The Canadian Hydroxychloroquine Study Group Sachet, J.C., Borba, E.F., Bonfá, E., Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients (2007) Lupus, 16 (4), pp. 273-278 Borba, E.F., Bonfa, E., Long term beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy (2001) J Rheumatol, 28, pp. 780-785 Wallace, D.J., Linker-Israeli, M., Metzger, A.L., Stecher, V.J., The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE (1993) Lupus, 2 (SUPPL. 1), pp. S13-S15 Kirou, K.A., Boumpas, D.T., Systemic glucocorticoid therapy in systemic lupus erythematosus (2007) Dubois lupus erythematosus, pp. 1175-1197. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins; Boumpas, D.T., Chrousos, G.P., Wilder, R.L., Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates (1993) Ann Intern Med, 119, pp. 1198-1208 Maccune, W.J., Marder, W.E., Riskalla, M., Immunossuppressive drug therapy (2007) Dubois lupus erythematosus, pp. 1198-1224. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins; Carneiro, J.R., Sato, E.I., Double blind, randomized, placebo controlled clinical trial of methotrexatc in systemic lupus erythematosus (1999) J Rheumatol, 26, pp. 1275-1279 Walchner, M., Messer, G., Kind, P., Phototesting and photoprotection in LE (1997) Lupus, 6, pp. 167-174 Vila, L.M., Mayor, A.M., Valentin, A.H., Association of sunlight exposure and photoprotection measures with clinical outcome. in systemic lupus erythematosus (1999) P R. Health Sci J, 18, pp. 89-94 Maggio, K.L., Singer, M.T., James, W.D., Clinical pearl: Discoid lupus erythematosus - treatment with occlusive compression (1996) J Am Acad Dermatol, 35, pp. 627-628 Rangel, L.V., Santiago, J.M., Souza, J.C.C., Terapia tópica com pimecrolimus ern lesão cutânea refratária de lupus eritematoso sistêmica. (2006) Rev Bras Reumatol, 46, pp. 230-233 Luger, T., Paul, C., Potential new indications of topical calcineurin inhibitors (2007) Dermatology, 215 (SUPPL. 1), p. 45 Costner, M.I., Sontheimer, R.D., Provost, T.T., Lupus erythematosus (2003) Cutaneous manifestations of rheumatic diseases, pp. 15-64. , Sontheimer RD, Provost TT, editors, Philadelphia: Lippincott Williams & Wilkins; Wenzel, J., Brähler, S., Bauer, R., Tüting, T., Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: Results of a retrospective study in 43 patients (2005) Br J Dermatol, 153, pp. 157-162 Callen, J.P., Spencer, L.V., Burruss, J.B., Holtman, J., Azathioprine: An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis (1991) Arch Dermatol, 127, pp. 515-522 Davis, J.C., Klippel, J.H., (2004) Antimalarials and immunossupressive therapies, pp. 1279-1281. , Systemic Lupus Erythematosus. 4th ed Bezerra, E.L.M., Vilar, M.J.P., Trindade Neto, P.B., Sato, E.I., Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus (2005) Arthritis Rheum, 52, pp. 3073-3078 Hall, R.P., Lawley, T.J., Smith, H.R., Katz, S.I., Bullous eruption of systemic lupus erythematosus: Dramatic response to dapsone therapy (1982) Ann Intern Med, 97, pp. 165-170 Cotell, S., Robinson, N.D., Chan, L.S., Autoimmune blistering skin diseases (2000) Am J Emerg Med, 18, pp. 288-299 Atra, E., Sato, E.I., Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide (1993) Clin Exp Rheumatol, 11, pp. 487-493 Coelho, A., Souto, M.I., Cardoso, C.R., Long-term thalidomide use in refractory cutaneous lesions in systemic lupus erythematosus: A 65 series of Brazilian patients (2005) Lupus, 14, pp. 434-439 Pisoni, C.N., Obermoser, G., Cuadrado, M.J., Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: Poor results with mycophenolate mofetil (2005) Clin Exp Rheumatol, 23, pp. 393-396 Schanz, S., Ulmer, A., Rassner, G., Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil (2002) Br J Dermatol, 147, pp. 174-178 Horizon, A.A., Weisman, M.H., Nonsteroidals and salicylates for systemic lupus erythematosus (2007) Dubois lupus erythematosus, pp. 1145-1151. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins; Williams, H.J., Egger, M.J., Singer, J.Z., Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus (1994) J Rheumatol, 21, pp. 1457-1462 Rahman, P., Humphrey-Murto, S., Gladman, D.D., Urowitz, M.B., Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis (1998) J Rheumatol, 25, pp. 243-246 Quismorici Jr, F.P., Hematologic and lymphoid abnormalities in systemic lupus erythematosus (2007) Dubois lupus erythematosus, pp. 801-828. , Wallace DJ, Hahn BH, editors, Philadelphia: Lippincott Williams & Wilkins; Gomard-Menesson, E., Ruivard, M., Koenig, M., Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases (2006) Lupus, 15, pp. 223-231 Jacob, H.S., Pulse steroids in hematologic diseases (1985) Hosp Pract (Off Ed), 20, pp. 87-94 Pirofsky, B., Immune haemolytic disease: The autoimmune haemolytic anaemias (1975) Clin Haematol, 4, pp. 167-180 Aviña-Zubieta, J.A., Galindo-Rodriguez, G., Robledo, I., Long-term effectiveness of danazol, corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus (2003) Lupus, 12, pp. 52-57 Alba, P., Karim, M.Y., Hunt, B.J., Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome (2003) Lupus, 12, pp. 633-635 Wang, S.-W., Cheng, T.-T., Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin-A (2005) Lupus, 14, pp. 483-485 Pignon, J.M., Poirson, E., Rochant, H., Danazol in autoimmune haemolytic anaemia (1993) Br J Haematol, 83, pp. 343-345 Perotta, S., Locatelli, F., La Manna, A., Anti-CD20 monoclonal antibody (rituximabe) for life-threatning autoimmune hemolytic anaemia in a patient with systemic lupus erythematosus (2002) Br J Haematol, 116, pp. 465-467 Majer, R.V., Hyde, R.D., High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia (1988) Clin Lab Haematol, 10, pp. 391-395 Kondo, H., Date, Y., Sakai, Y., Effective simultaneous rhG-CSF and methylprednisolone pulse therapy in agranulocytosis associated with systemic lupus erythematosus (1994) Am J Hematol, 46, pp. 157-158 Euler, H.H., Harten, P., Zeuner, R.A., Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections (1997) J Rheumatol, 24, pp. 215-237 Cervera, H., Jara, L.J., Pizarro, S., Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans syndrome (1995) J Rheumatol, 22, pp. 1867-1871 Roach, B.A., Hutchinson, G.J., Treatment of refractory, systemic lupus erythematosusassociated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide (1993) Arthritis Rheum, 36, pp. 682-684 Arnal, C., Piette, J.C., Leone, J., Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases (2002) J Rheumatol, 29, pp. 75-83 Goebel, K.M., Gassel, W.D., Goebel, F.D., Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus (1973) Scand J Haematol, 10, pp. 28-34 Vasoo, S., Thumboo, J., Fong, K.Y., Refractory immune thrombocytopenia in systemic lupus erythematosus: Response to mycophenolate mofetil (2003) Lupus, 12, pp. 630-632 Quartucio, L., Sacco, S., Franzolini, N., Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus (2006) Lupus, 15, pp. 76-79 Shanafelt, T.D., Madueme, H.L., Wolf, R.C., Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura,autoimmune hemolytic anemia,and Evans syndrome (2003) Mayo Clin Proc, 78, pp. 1340-1346 Ten Cate, R., Smiers, F.J., Bredius, R.G., Anti-CD20 monoclonal antibody(rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus (2004) Rheumatology (Oxford), 43, p. 244 Ter Borg, E.J., Kallenberg, C.G., Treatment of severe thrombocy-topenia in systemic lupus erythematosus with intravenous gammaglobulin (1992) Ann Rheum Dis, 51, pp. 1149-1151 Chandramouli, N.B., Rodgers, G.M., Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia (2000) Am J Hematol, 65, pp. 85-86 You, N.Y., Tefferi, A., Nagorney, D.M., Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus (2004) Ann Surg, 240, pp. 286-296 Maksimowicz-McKinnon, K., Manzi, S., Cardiovascular manifestations of lupus (2007) Dubois lupus erythematosus, pp. 663-677. , Wallace DJ, Hahn BH, editors, Philadelphia: Lippincott Williams & Wilkins; Westerweel, P.E., Luyten, R.K., Koomans, H.A., Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus (2007) Arthritis Rheum, 56 (5), pp. 1384-1396 Manzi, S., Meilahn, E.N., Rairie, J.E., Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study (1997) Am J Epidemiol, 145 (5), pp. 408-415 Petri, M., Lakatta, C., Magder, L., Goldman, D., Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis (1994) Am J Med, 96, pp. 254-259 Petri, M., Kiani, A.N., Post, W., Magder, L., Lupus Atherosclerosis Preventio Study (LAPS): A randomized double blind placebo controlled trial of atorvastatin versus placebo (2006) Arthritis Rheum, 54 (SUPPL.), p. 520. , S Ferreira, G.A., Navarro, T.P., Telles, R.W., Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: An 8 weeks controlled trial (2007) Rheumatology (Oxford), 46 (10), pp. 1560-1565 D'Cruz D, Khamashta MA, Hughes G: Pulmonary manifestations of systemic lupus erythematosus. In: Wallace DJ, Hahn BH. Dubois' Lupus Erythematosus. Philadelphia, 7th ed. Lippincott Williams & Wilkins 2007. p. 678-99Man, B.L., Mok, C.C., Serositis related to systemic lupus erythematosus: Prevalence and outcome (2005) Lupus, 14, pp. 822-826 Kao, A.H., Manzi, S., How to manage patients with cardiopulmonary disease? (2002) Best Pract Res Clin Rheumatol, 16, pp. 211-227 McKnight, K.M., Adair, N.E., Agudelo, C.A., Successful use of tetracycline pleurodesis to treat massive pleural effusion secondary to systemic lupus erythematosus (1991) Arthritis Rheum, 34, pp. 1483-1484 Schwab, E.P., Schumacher Jr, H.R., Freundlich, B., Callegari, P.E., Pulmonary alveolar hemorrhage in systemic lupus erythematosus (1993) Semin Arthritis Rheum, 23, pp. 8-15 Weinrib, L., Sharma, O.P., Quismorio Jr, F.P., A long-term study of interstitial lung disease in systemic 1upus erythematosus (1990) Semin Arthritis Rheum, 20, pp. 48-56 Okada, M., Suzuki, K., Matsumoto, M., Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases (2007) Mod Rheumatol, 17, pp. 131-136 Heresi, G.A., Minai, O.A., Lupus-associated pulmonary hypertension: Long-term response to vasoactive therapy (2007) Respir Med, 101, pp. 2099-2107 Denton, C.P., Humbert, M., Rubin, L., Black, C.M., Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions (2006) Ann Rheum Dis, 65, pp. 1336-1340 Galiè, N., Manes, A., Farahani, K.V., Pulmonary arterial hypertension associated to connective tissue diseases (2005) Lupus, 14, pp. 713-717 Sanchez, O., Sitbon, O., Jaïs, X., Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension (2006) Chest, 130, pp. 182-189 The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42: 599-608, 1999Boumpas, D.T., Yamada, H., Patronas, N.J., Pulse cyclophosphamide for severe neuropsychiatric lupus (1991) Q J Med, 81, pp. 975-984 West SG: The nervous system. In: Wallace DJ, Hahn BH. Dubois' Lupus Erythematosus. Philadelphia. 7th ed. Lippincott Williams & Wilkins 2007. p. 707-46Barile, L., Lavalle, C., Transverse myelitis in systemic lupus erythematosus - the effect of IV pulse methylprednisolone and cyclophosphamide (1992) J Rheumatol, 19, pp. 370-372 Tokunaga, M., Saiko, K., Kawabata, D., Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system (2007) Ann Rheum Dis, 66, pp. 470-475 Dooley MA: Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH. Dubois' Lupus Erythematosus. Philadelphia, 7th ed. Lippincott Williams & Wilkins 2007. p. 1112-30Grande, J.P., Ballow, J.E., Renal biopsy in lupus nephritis (1998) Lupus, 7, pp. 611-617 Weening, J.J., D'Agati, V.D., Schwartz, M.M., The classification of glomerulonephritis in systemic lupus erythematosus revisited (2004) J Am Soc Nephrol, 15 (2), pp. 241-250 Weening, J.J., D'Agati, V.D., Schwartz, M.M., The classification of glomerulonephritis in systemic lupus erythematosus revisited (2004) Kidney Int, 65 (2), pp. 521-530 The American College of Rheumatology response criteria for proliferative and membranous renal disease in SLE clinical trials (2006) Arthritis Rheum, 54, pp. 421-432. , Renal disease subcommitee of the ACRAd Hoc Committee on SLE response criteria Ruggenenti, P., Perna, A., Gherardi, G., Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy (1998) Lancet, 352, pp. 1252-1256 Praga, M., Slowing the progression of renal failure (2002) Kidney Int, (SUPPL. 80), pp. 18-22 Pollak, V.E., Treatment of lupus nephritis (1983) Nippon Jinzo Gakkai Shi, 25, pp. 776-785 Kimberly, R.P., Lockshin, M.D., Sherman, R.L., High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus (1981) Am J Med, 70, pp. 817-824 Austin 3rd, H.A., Klippel, J.H., Balow, J.E., Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs (1986) N Engl J Med, 314, pp. 614-619 Balow, J.E., Choosing treatment for proliferative lupus nephritis (2002) Arthritis Rheum, 46, pp. 1981-1983 Flanc, R.S., Roberts, M.A., Strippoli, G.F., Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials (2004) Am J Kidney Dis, 43, pp. 197-208 Bansal, V.Y., Beto, J.A., Treatment of lupus nephritis: A meta-analysis of clinical trials (1997) Am J Kidney Dis, 29, pp. 193-199 Chan, T.M., Li, F.K., Tang, C.S., Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis (2000) Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med, 343, pp. 1156-1162 Houssiau, F.A., Vasconcelos, C., D'Cruz, D., Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide (2002) Arthritis Rheum, 46, pp. 2121-2131 Contreras, G., Pardo, V., Leclercq, B., Sequential therapies for proliferative lupus nephritis (2004) N Engl J Med, 350, pp. 971-980 Ginzler, E.M., Aranow, C., Buyon, J., A multicenter study of MMF Vs IV cyclophosphamide as induction therapy for severe lupus nephritis: Preliminary results (2005) N Eng J Med, 353, pp. 2219-2228 Sinclair, A., Appel, G., Dooley, M.A., Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: Rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) (2007) Lupus, 16 (12), pp. 972-980 Kolasinski, S.L., Chung, J.B., Albert, D.A., What do we know about lupus membranous nephropathy? An analytic review (2002) Arthritis Rheum, 47, pp. 450-455 Chan, T.M., Li, F.K., Hao, W.K., Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression (1999) Lupus, 8, pp. 545-551 Radhakrishnan, J., Kunis, C.L., D'Agati, V., Appel, G.B., Cyclosporine treatment of lupus membranous nephropathy (1994) Clin Nephrol, 42, pp. 147-154 Mok, C.C., Ying, K.Y., Lau, C.S., Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: An open-label trial (2004) Am J Kidney Dis, 43, pp. 269-276 Botha, E.F., Guedes, L.K., Christmann, R.B., Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria (2006) Rheumatol Int, 26 (12), pp. 1078-1083 Sabahi, R., Anolik, J.H., B-cell-target for SLE (2006) Drugs, 66 (15), pp. 1933-1948 Bhat, P., B lymphocytes and lupus nephritis: New insights into pathogenesis and targeted therapies (2008) Kidney Int, 73, pp. 261-268 Stone, J.H., End-stage renal disease in lupus: Disease activity, dialysis, and the outcome of transplantation (1998) Lupus, 7, pp. 654-659 Urowitz, M.B., Gladman, D.D., Farewell, V.T., Lupus and pregnancy studies (1993) Arthritis Rheum, 36, pp. 1392-1397 Clowaw, M.E., Magder, L.S., Petri, M., The impact of increased lupus activity on obstetric outcomes (2005) Arthritis Rheum, 52, pp. 514-521 Sánchez-Guerrero, J., Uribe, A.G., Jiménez-Santana, L., A trial of contraceptive methods in women with Systemic lupus erythematosus (2005) N Engl J Med, 353, pp. 2539-2549 Petri, M., Kim, M.Y., Kalunian, K.C., OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus (2005) N Engl J Med, 353, pp. 2550-2558 Buyon, J.P., Kalunian, K.C., Ramsey-Goldman, R., Assessing disease activity in SLE patients during pregnancy (1999) Lupus, 8, pp. 677-684 Petri, M., (2003) Pregnancy in SLE, pp. 1427-1430. , ed. Rheumatology. 3th. ED; Wilson, W.A., Gharavi, A.E., Koike, T., International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop (1999) Arthritis Rheum, 42, pp. 1309-1311 Buyon, J.P., Clancy, R.M., Neonatal lupus syndromes (2003) Curr Opin Rheumatol, 15, pp. 535-541 Cervera, R., Font, J., Carmona, F., Balasch, J., Pregnancy outcome in systemic lupus erythematosus: Good news for the new millennium (2002) Autoimmun Rev, 1, pp. 354-359 Anderson, P.O., Drugs and breast feeding (1979) Semin Perinatol, 3, pp. 271-278 Bermas, B.L., Hill, J.A., Effects of immunosuppressive drugs during pregnancy (1995) Arthritis Rheum, 38, pp. 1722-1732 Levy, R.A., Vilela, V.S., Cataldo, M.J., Hydroxychloroquine in lupus pregnancy: Double-blind and placebo-controled study (2001) Lupus, 10, pp. 401-404 Ost, L., Wettrell, G., Bjorkhem, I., Rane, A., Prednisolone excretion in human milk (1985) J Pediatr, 106, pp. 1008-1011 Petri, M., Hydroxychloroquine use in Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis (1996) Lupus, 5 (SUPPL. 1), pp. S16-S22 Bertolaccini, M.L., Khamashta, M.A., Laboratory diagnosis and management challenges in the antiphospholipid syndrome (2006) Lupus, 15, pp. 172-178 Jungers, P., Dougados, M., Pélissier, C., Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus (1982) Arthritis Rheum, 25 (6), pp. 618-623 Mintz, G., Gutiérrez, G., Delezé, M., Rodríguez, E., Contraception with progestagens in systemic lupus erythematosus (1984) Contraception, 30 (1), pp. 29-38 Buyon, J.P., Petri, M.A., Kim, M.Y., The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial (2005) Ann Intern Med, 142, pp. 953-962 Sánchez-Guerrero, J., González-Pérez, M., Durand-Carbajal, M., Menopause hormonal therapy in women with systemic lupus erythematosus (2007) Arthritis Rheum, 56 (9), pp. 3070-3079 Lahita, R.G., Hormonal contraception and replacement and the use of androgens in the antiphospholipid syndrome (2000) J Autoimmun, 15, pp. 213-216 Klippel, J.H., Karsh, J., Stahl, N.I., A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus (1979) Arthritis Rheum, 22, pp. 1321-1325 Abu-Shakra, M., Zalmanson, S., Neumann, L., Influenza virus vaccination of patients with systemic lupus erythematosus: Effects on disease activity (2000) J Rheumatol, 27, pp. 1681-1685 O'Neill, S.G., Isenberg, D.A., Immunizing patients with systemic lupus erythematosus: A review of effectiveness and safety (2006) Lupus, 15 (11), pp. 778-783 Kuruma, K.A., Borba, E.F., Lopes, M.H., Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus (2007) Lupus, 16 (5), pp. 350-354 Liang, M.H., Fortin, P.R., Isenberg, D.A., Snaith, L., Quantitative clinical assessment of disease activity in systemic lupus erythematosus: Progress report and research agenda (1991) Rheumatol Int, 11, pp. 133-136 Strand, V., Gladman, D., Isenberg, D., Outcome measures to be used in clinical trials in systemic lupus erythematosus (1999) J Rheumatol, 26, pp. 490-497 Strand, V., Gladman, D., Isenberg, D., Endpoints: Consensus recommendations from OMERACT IV (2000) Lupus, 9, pp. 322-327 Bombardier, C., Gladman, D.D., Urowitz, M.B., Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE (1992) Arthritis Rheum, 35 (6), pp. 630-640 Gladman, D.D., Ibañez, D., Urowitz, M.B., Systemic lupus erythematosus disease activity index 2000 (2002) J Rheumatol, 29, pp. 288-291 Machado, C., Ruperto, N., Consenso em Reumatologia Pediátrica Parte II - definição de melhora clínica para o lúpus critematoso sistêmico e dermatomiosite juvenil. (2005) Rev Bras Reumatol, 45 (1), pp. 14-19 Gladman, D., Ginzler, E., Goldsmith, C., The development and initial validation of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index for systemic lupus erythematosus (1996) Arthritis Rheum, 39 (3), pp. 363-369 Gladman, D.D., Goldsmith, C.H., Urowitz, M.B., The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison (2000) J Rheumatol, 27 (2), pp. 373-376